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Introduction
Mammalian mitochondria contain their own genome, a circular 16.5 kb mitochondrial DNA (mtDNA) that encodes genes for 13 polypeptides, 22 tRNA, and 2 rRNA. Mitochondrial DNA is replicated by human polymerase γ, and the amount of mtDNA per cell can vary according to biogenesis and retrograde regulation. This regulation is affected by cell type and cellular energy demands, but can also be influenced by mitochondrial disease or dysfunction, acquired drug-related mitochondrial toxicity (Gerschenson and Brinkman 2004) , and oxidative stress from various sources such as aging, cancer, and smoking (Cote 2005; Masayesva, Mambo et al. 2006; Higuchi 2007; Copeland 2008) . Quantification of the relative ratio between mtDNA and nuclear DNA, the latter usually assumed to remain constant in human tissue, is therefore relevant to the study of many diseases and conditions, using either clinical, animal or cultured cell derived samples.
In 2005, representatives from 18 research groups around the world mostly involved in HIV drug toxicity research met for the first technical meeting of mtDNA researchers in Boston. During the meeting, methodologies were shared and the usefulness and standardization of mtDNA quantification between laboratories were discussed. Later that year, during a second meeting of the same group in Dublin, it was agreed that mtDNA quantity should be expressed as mtDNA/nDNA ratio as opposed to mtDNA copies per cell as few assays actually count cells but rather assume 2 copies of nDNA per cell, which is not true for all human tissues. The term MITONAUTS, standing for MITOchondria Network for Assay Utilization and Technique Standardization was coined and the present study designed, to compare mtDNA quantification between laboratories. The goal of this study was to assess the concordance between laboratories that quantify mtDNA using varied quantitative PCR assays and to assess how shipping affected the values.
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Materials and methods
For ethical and international shipping regulation issues, we elected to use DNA extracted from human cell lines as opposed to human clinical samples. This presented definite advantages but also raised some comparison issues as discussed later. Table 1 summarizes the source of the human DNA samples. For the first shipment, total DNA was extracted from cultured human cells (see Table 1 , left column) using QiaAmp DNA midi kit (Qiagen, Hilden, Germany). The DNA was resuspended in Tris-EDTA buffer and aliquoted (50 µL per tube). For sample #9, a larger volume (200 µL) of DNA was provided, to be used as internal control in future experiments. The first shipment samples' DNA concentration ranged from 57 to 150 ng/µL.
DNA preparation
For the second shipment, DNA was also extracted from cultured human cells (see Table 1 , right column) using the QiaAmp DNA mini kit (QIAGEN) and resuspended in Tris-EDTA buffer. The samples'DNA concentration ranged from 11 to 67 ng/µL.
In several instances, samples were prepared by treating a single cell line with drugs that modulate mtDNA content. For example, in the first shipment, four samples were derived from CEM cells exposed to nucleoside reverse transcriptase inhibitors (NRTI) for 7 days (Galluzzi, Pinti et al. 2005 ) while in the second shipment, 11 of the 20 samples were DNA extracted from K562 cells exposed to the NRTI zidovudine or stavudine (Papp, Gadawski et al. 2008 ).
Shipping
For the first shipment, two identical sets of 19 DNA samples were shipped by courier (DHL) to each participating laboratory from Modena, Italy, at room temperature. Each site was asked to ship one set back to the sender, also at room temperature to evaluate if shipping added to variability. For the second shipment, a single set of 20 DNA samples was shipped on dry ice from Vancouver, Canada, by FEDEX.
MtDNA quantification assays
Each site used its own mtDNA quantification assay methodology and reagents. Details on the methods used are presented in Table 2 , in alphabetical order (unrelated to the order of the other result tables). One site (Barcelona I) used a different nuclear gene when assaying the second shipment as the
gene typically used to quantify mtDNA depletion in human clinical samples yielded different results in cell line-derived samples. It was agreed that the data would remain anonymous. For this study, the free software Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to blast the human genome with each set of primer against its intended target, under 55ºC to 63ºC PCR conditions.
The size of the amplified fragment and the likelihood of amplifying unintended targets with each primer pair, based on the Primer-BLAST results, are reported in Table 2 .
Statistical considerations
For statistical analyses, mtDNA/nDNA values were compared using Pearson's correlations (XLstat 2009). For correlations, data from all sites were included. However, when analyzing variability between sites, data from site #2 were omitted since that site reported relative mtDNA/nDNA content and not the absolute ratio as for the other sites. Statistical analyses were performed on both raw and log 10 -transformed data due to the wide variability of the data. M A N U S C R I P T Table 3 , ten of the eleven returned sets of samples gave values that were generally higher than those of the reference set, with the traveling set showing an average change in mtDNA/nDNA ratio of +88% compared to the non-traveling set. Of note, the two sets of sample showing the lowest correlations between the reference mtDNA/nDNA ratio measured by Modena and the returned set of samples (Table 3 ) also happened to be those that traveled the longest distance.
MtDNA/nDNA concordance between sites
Eight sites submitted mtDNA/nDNA ratio data for the 19 samples. Data from one site (#2) were expressed as relative rather than absolute mtDNA/nDNA ratios with values approximately 300 times lower than all others. For that reason these data were only included in correlation analyses. Using both raw and log 10 -transformed data, results from each site were correlated to those of the other 8 sites individually (Table 4A ). In this one on one comparison between each of the participating sites, five sites showed good correlations between them (#1, 3, 6, 8 and 9, all p<0.0001) while site #7 showed weaker correlation with those same five sites (raw data R 2 ≥0.272, p≤0.022; log 10 R 2 =0.250, p≤0.029).
Three sites (#2, 4 and 5) showed poor correlation with the other sites with the exception that site 2 showed a strong correlation with site 4 (raw data R 2 =0.485, p=0.001; log 10 R 2 =0.479, p=0.001) and a weak one with site 7 (raw data R 2 =0.266, p=0.024; log 10 R 2 =0.204, p=0.052). This discordance was greatly ameliorated by excluding samples extracted from the Molt-4 cell line (samples 15 and 16), although site #5 remained poorly correlated to others (Table 4B) .
MtDNA/nDNA measurement variability
The mean values and the inter-site coefficient of variation (%CV=mean*100%/standard deviation (SD) were calculated for each sample shipped (Table 1) . For this calculation, site #2 was omitted since their data was on a relative scale. The average CV mean ± SD (range) for all samples was (raw data 94 ± 23 (50-142) %; log 10 15.0 ± 4.8 (7.5-23.6) %). This decreased to (raw data 44 ± 8
(32-55) %, log 10 10.7 ± 4.2 (4.1-18.1) %) if data from sites 4 and 5 were also omitted. There was no relationship between the samples' DNA concentration and their inter-site CV. This remained true with or without sites 2, 4 and 5.
Second shipment on dry ice
Sets of 20 DNA samples on dry ice were sent from Vancouver to eight laboratories, all were confirmed to have arrived still frozen except the shipment to Australia that was cold. Each site determined the mtDNA content of the samples, expressed as the mtDNA/nDNA ratio, and sent data back. As before, site 2 data were on a relative scale rather than an absolute one. While assaying samples from the second shipment, two sites noticed that, for some samples, their mtDNA/nDNA measurements showed gene-dependent variability and accordingly, sent back results that they considered reliable for 11/20 and 13/20 samples, respectively.
Concordance between duplicate samples
Within the 20 samples, two were present in duplicate (#6 was a duplicate of #19 and #12 of #20) ( Table 1 ), something that was not known by the participants. Seven sites provided data for these samples. The absolute % difference between the duplicates (∆ between duplicates*100%/mean of duplicates) was calculated for each pair and averaged. Results (mean % difference ± SD (range) raw 11.7 ± 7.4% (0.8-26.3%); log 10 1.8 ± 1.3% (0.2-4.2%) indicated generally good concordance between duplicates as six out of seven sites showed less than 15% (raw data) difference between duplicates.
MtDNA/nDNA concordance between sites
As before, for all 20 samples, results from each site were correlated to those of the other 8 sites individually, using both raw and log 10 -transformed data (Table 5A ). This one on one comparison between the sites revealed that all sites showed good correlation between them except one site (#4) that showed generally poor correlation with most sites. However, site #4 was strongly correlated with site values given the reduced sample size (N=11 instead of 20) (Table 5B) . Notably, when all samples compared were derived from the same cell line, site #4 showed much improved correlations with the other sites.
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MtDNA/nDNA measurement variability
The mean of the coefficient of variability between sites for all 20 samples (mean CV ± SD
[range]) was (raw data 79 ± 48 [37-212] %; log 10 24 ± 10 [9-35] %) ( Table 1) 
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Discussion
The various assays used in this study were internally reliable. However, more work is needed before absolute quantification of mtDNA is sufficiently reproducible across laboratories to allow direct comparison between them, or development of clinically meaningful normal range values for use in clinical diagnosis and monitoring. Although mtDNA is a material of choice for forensic nucleic acid analyses and is known for its relative stability, travel at room temperature, though very affordable, did not favor mtDNA/nDNA measurement reproducibility. The apparent increase in mtDNA/nDNA content observed was likely caused by partial degradation of the nDNA during transport. This also implies that the standard sample that was distributed for future standardization between laboratories cannot be used for this purpose as it was part of the room temperature shipment. Alternatively, it is possible that partial degradation of the DNA linearized the mtDNA, rendering it more accessible to polymerases. From this exercise, it would clearly be recommended that DNA samples be kept frozen until analyzed. Because of this, the correlations between sites presented in Tables 4A and 4B should be interpreted with caution, as DNA degradation was likely a factor. Nevertheless, 6 of the 9 sites demonstrated good concordance between them.
For the second shipment on dry ice, in agreement with observations from a previous smaller study (Hammond, Sayer et al. 2003) , good correlation was observed between 8 of the 9 sites.
However, significant variability between sites remained with respect to the absolute mtDNA/nDNA values. This was illustrated by the inter-site CV which was above 200% for some samples derived from the CRL 2061 cell line, a high figure considering that intra-site variability (CV) for mtDNA/nDNA assay is typically ≤15%. Log 10 -transforming the data reduced the inter-site variability, as could be expected. A number of factors could influence the variability in mtDNA/nDNA values measured between sites. These include but are not restricted to the specificity of the assay primers and the specificity of the detection method used (SYBR green vs. fluorescent probes), the copy number of the nuclear gene amplified, potential polymorphisms and DNA rearrangements, the target gene's PCR efficiencies, and the methodology itself. A total of nine different assays were used among the participating sites, and the two sites using the same primer sets did not show higher than average correlation between them. This may be due to the fact that different detection systems were used.
Each assay uses unique sets of primers targeting a mitochondrial gene and a nuclear DNA gene.
Some of the variability observed between the sites is intrinsic to the genes and primers they use to
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10 amplify the DNA as even within laboratories, some genes can yield more variable results than others.
Insufficient specificity on the part of the nDNA primers would evidently impact this assay. Should any of the primers amplify unintentional targets such as pseudogenes or nuclear genes that are subject to chromosomal rearrangements, the value of the mtDNA/nDNA ratio would be affected. Nuclear DNA primers should ideally be targeted toward single-copy nuclear genes having low incidence of interindividual polymorphisms and mutations. If a high copy number gene is chosen, the exact number of copies should be considered if the mtDNA/nDNA ratio is to be compared to that generated using single copy nuclear genes. Of course, the PCR efficiency of both the mtDNA and nDNA amplicons should be highly similar and the DNA concentration range yielding stable mtDNA/nDNA should be determined. Nuclear DNA non-coding pseudogenes, although less common than mitochondrial pseudogenes (Zhang and Gerstein 2004) , are especially prevalent for ribosomal RNA genes (GriffithsJones 2007). Indeed, based on Primer-BLASTing, some assays used in this study may have unintentionally amplified other products including nuclear target pseudogenes with high or even complete homology. These homologous DNA amplicons may be undetectable by the T m curve often used to evaluate PCR primer's specificity, yet they would significantly decrease mtDNA/nDNA ratio.
In addition, it is well recognized that chromosomal rearrangements, resulting in copy number variants, occur within the human genome. Although copy number variants have been associated with disease and malignancies (Conrad and Antonarakis 2007; Cooper, Nickerson et al. 2007) , and are known to exist in several of the cell lines used in this study (Cottier, Tchirkov et al. 2004) , they are also found in healthy individuals and are more common than initially expected (Scherer, Lee et al. 2007; Perry, Yang et al. 2008) . As the cell lines used for this study are transformed and mostly derived from cancer patients, their DNA could bear important chromosomal rearrangements that may or may not affect amplification by primers targeting genes that vary from one assay to another. This could be at least partially responsible for the higher inter-site variability observed with some samples. Given that quantification can be nDNA gene-specific, consistent results with two independent nDNA genes can help rule out the possibility of unintended nuclear amplification.
Mitochondrial DNA pseudogenes are very common throughout the nuclear genome (Bensasson, Zhang et al. 2001; Yao, Kong et al. 2008 ) and pose many challenges to mtDNA research.
As they can vary from one individual to another, from one cell line to another, some of the variability observed between the sites could be explained by mitochondrial pseudogenes. Testing two mtDNA genes rather than one or using Rho(o) cell (Hashiguchi and Zhang-Akiyama 2009 ) DNA as template
would confirm the absence of mitochondrial pseudogene amplification. Using a single type of cultured cells when studying mtDNA quantification in would avoid many of the issues raised above.
Sequencing of the human genome and tools such as BLAST and Primer-BLAST can greatly assist in the design of assay primers. Of note, many primers used in this study were designed before the availability of these tools. Future studies such as this one should consider reporting not only the mtDNA/nDNA ratio but rather each gene copy number separately. This would allow the assessment of accuracy and concordance across sites and would give information on whether the source of discordance lies with the mitochondrial or the nuclear gene quantification.
The fact that all sites showed high concordance for the K562-only derived samples reinforces the likelihood that single vs. multicopy genes, cell line-specific DNA alterations and/or polymorphisms may have affected the performance or applicability of some assays. As several of the samples were extracted from cells exposed to drugs such as zidovudine, stavudine or simvastatin, there is a remote possibility that the drugs may affect the primer binding sites, hence the assay. From this data, it is difficult to ascertain how these factors may influence mtDNA measurements in human clinical samples from various genetic make-up and for the study of various diseases, however one can assume that clinical samples may harbor fewer chromosomal rearrangements than transformed cell lines. These results suggest that mtDNA quantification assays need to be designed carefully and several specific recommendations can be made based on this study to increase reproducibility and accuracy of mtDNA/nDNA determinations, in addition to the usual qPCR assay design steps.
Conclusions
Our results showed good correlation between laboratories, indicating that within lab comparisons or comparison of relative mtDNA/nDNA between labs should be reliable. However, absolute mtDNA/nDNA ratio values were highly variable across sites, something that is probably partially due to the fact that samples were derived mostly from transformed cultured cells.
Furthermore, our results indicated that for such measurement as mtDNA/nDNA ratio, transportation of samples must take place under frozen conditions. Although human clinical samples may have yielded less variable results, further efforts in standardization and evaluation of proficiency in reporting mtDNA content are clearly needed if the goal is to standardize mtDNA content reporting and establish clinically relevant reference ranges for disease states, in order to assist clinical care and research.
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12 a, CEM 1-4 were derived from the same cell line exposed to NRTIs for 7 days (Galluzzi, Pinti et al. 2005) ; b, the K562 samples were all derived from the same cell line exposed to various concentrations of zidovudine or stavudine for several weeks (Papp, Gadawski et al. 2008 ); c, the three CRL 2061 samples were derived from the same primary cell line differentiated into muscle cells and exposed to 0.1 µM simvastatin (personal communication from Cote); d, sample #19 is a duplicate of sample #6; e, sample #20 is a duplicate of sample #12. a In some instances, the assay did not meet the assay quality control and no value was generated. b The correlations were between the measurements made by the Modena laboratory on the set of samples assigned to their site and each of the sample sets shipped back from the participating sites. A C C E P T E D M A N U S C R I P T 
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